戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1  received bilateral orthotopic injections of syngeneic 67NR, 4T07, or 4T1cells (1 x 10(5) cells per i
2  determined after intravenous inoculation of syngeneic 9801L pancreas carcinoma cells.
3  simulated by using bone graft material from syngeneic ACTB-eGFP-expressing mice.
4 ed ASNase efficacy in mice transplanted with syngeneic ALL cells and, like in humans, without affecti
5                      One patient underwent a syngeneic allograft and 25 HDM/ASCT (16 of whom subseque
6           DHB had no effect on the growth of syngeneic allografts in wild-type mice but opposed the a
7                                              Syngeneic and allogeneic cardiospheres attenuated the in
8 In vivo, cell engraftment was similar in the syngeneic and allogeneic groups 1 week and 3 weeks after
9 first days after embryo implantation in both syngeneic and allogeneic matings; express the markers of
10 s producing insulin after transplantation in syngeneic and allogeneic recipients.
11   B-cell reconstitution is abrogated in both syngeneic and allogeneic transplantation using Treg-depl
12 t of an antibody-mediated CD47 blockade in a syngeneic and an allogeneic DCD rat kidney transplant mo
13  expression of PD-L1, which was confirmed in syngeneic and genetically engineered mouse models of lun
14 iferated more in response to Ag presented by syngeneic APC than the same T cell subset from healthy a
15 ce, C1q-deficient (C1qa(-/-)) mice bearing a syngeneic B16 melanoma exhibit a slower tumour growth an
16 ti-PD-L1, but not anti-CTLA4, therapy in the syngeneic B16F10 melanoma model.
17 udy, we show that the growth of transplanted syngeneic B16F10 melanoma or Lewis lung carcinoma cells
18 fails to generate antitumor immunity against syngeneic B16F10 tumors in mice.
19                              In vivo, both a syngeneic (B6-to-B6) marginal mass islet transplant mode
20 e immunized against platelets from wild-type syngeneic BALB/c (CD61(+)/H-2(d)), allogeneic C57BL/6 (C
21 n of a GR9-B11 mouse fibrosarcoma clone into syngeneic BALB/c mice, all animals remained free of spon
22 pic breast cancer model using 4T1luc-bearing syngeneic BALB/c mice.
23 ration by dilution of transferred cells into syngeneic BALB/c recipients.
24                 Our results demonstrate that syngeneic bile duct antigens efficiently break immune to
25 autoimmune cholangitis via immunization with syngeneic bile duct protein (BDP).
26 ansfer of T cells from transplanted nudes to syngeneic black-coated RAG(-/-) recipients caused progre
27 though CMV infection was self-limiting after syngeneic BMT, in the presence of GVHD after allogeneic
28 th equal potency to those administered after syngeneic BMT.
29 es the development of autoimmune disorder in syngeneic BMTs.
30                                    Using our syngeneic bone marrow transplant (BMT) mouse model, BMT
31  cells were repopulated to a normal level by syngeneic bone marrow transplantation.
32 on analyses combined with in vivo studies in syngeneic breast cancer models demonstrate the participa
33                                         In a syngeneic breast cancer mouse model overexpressing GLUT1
34 use HCC cells (Hepa1-6) were inoculated into syngeneic C57BL/6 mice, intratumoral injection of adenov
35 ies of the promising cationic amphiphiles in syngeneic C57BL/6J mice under prophylactic settings.
36 injected B16rho(0) mouse melanoma cells into syngeneic C57BL/6N(su9-DsRed2) mice that express red flu
37     We demonstrated that both allogeneic and syngeneic CAR T cells show initial expansion as effector
38 y of diabetes reversal of allogeneic but not syngeneic CC islets was lower than that of naked islets,
39                         We have isolated two syngeneic cell lines (indolent and aggressive) through i
40 ntation of green fluorescent protein-labeled syngeneic colorectal cancer cells.
41  a diminished 5-FU therapeutic response in a syngeneic colorectal tumor model consistent with increas
42 the bacterial population dynamics in ectopic syngeneic colorectal tumours in mice via a luminescent r
43  compared to 93% (71-104) and 82% (59-90) in syngeneic controls (P=0.006 and 0.03).
44                                Compared with syngeneic controls, RIC mice with GVHD showed evidence o
45 d from draining lymph nodes of allogeneic or syngeneic corneal transplanted BALB/c mice.
46 ed inflammation when they were recipients of syngeneic corneal transplants but also exhibited signifi
47 d intracoronarily vehicle or 1 million male, syngeneic CPCs.
48 ltivalent M2pep and M2pepKLA analogs using a syngeneic CT-26 tumor cell suspension.
49         Consistent with these advantages, in syngeneic CT26 tumor models, high-affinity PD-1 was effe
50 s, this original demonstration used congenic/syngeneic dam and foster pup pairs.
51                                         In a syngeneic DLBCL mouse model, this PARP1-targeted PET ima
52 ion of hapten conjugated to self-antigens of syngeneic erythrocytes and subsequent contact immunizati
53 specific STAT3-knockdown postnatal mice-plus syngeneic fibroblast cell-transplant models-we demonstra
54 sCD and tested in animal models of human and syngeneic GBM.
55    Similar growth inhibition was observed in syngeneic GL261 GBM (p < 0.05).
56           We treated mice bearing orthotopic syngeneic (Gl261) GBMs or human (MGG8) GBM xenografts wi
57 B signaling (p65) in myeloid cells inhibited syngeneic glioblastoma (GBM) through decreased CD45 infi
58                         Furthermore, using a syngeneic glioma model, w-MWNT-ANG showed enhanced uptak
59 l survival of tumor-bearing mice in the GL26 syngeneic glioma model.
60 rates that resistance to MYXV virotherapy in syngeneic glioma models involves a multifaceted cellular
61                   Finally, in mice harboring syngeneic gliomas, an inhibitor of 2HG synthesis complem
62 geneic grafts without cold ischemia time and syngeneic grafts did not develop any TV.
63                                 In contrast, syngeneic grafts in the same mice elicited transient and
64 he airway epithelium was mostly preserved in syngeneic grafts, mostly destroyed in the KCa3.1 and TRA
65 the survival or histology of DST/MR1-treated syngeneic heart grafts, the latter indicating that persi
66  cytomegalovirus (anti-MCMV) responses after syngeneic hematopoietic stem cell transplantation (HSCT)
67  Compound 3c almost eliminated the growth of syngeneic hepatocellular carcinoma in Balb/c mice, sugge
68 nificantly inhibited in vivo the growth of a syngeneic hepatocellular carcinoma in Balb/c mice.
69 ated events in the liver after transplanting syngeneic hepatocytes into dipeptidyl peptidase IV-defic
70                                         In 2 syngeneic HER2+ self-antigen tumor models, we found that
71                                         In a syngeneic HLA-A2-transgenic mouse model of large establi
72 er cell line Panc02 into the pancreas of the syngeneic host C57BL/6.
73  developed murine models of this disease, in syngeneic hosts as well as in nonobese diabetic/severe c
74 51 days), and old (736 days) C57BL/6 mice as syngeneic hosts for engraftment of Lewis lung cancer to
75                            In CD47-deficient syngeneic hosts, engrafted B16 melanomas were 50% more s
76 tive phenotypic traits after transmission to syngeneic hosts.
77 radiotherapeutic response in immunocompetent syngeneic hosts.
78 ive mammary cancer metastasis to the lung of syngeneic hosts.
79 ion gp96-Ig within 2 weeks of T cell-replete syngeneic HSCT led to cross-presentation and increased s
80                                           In syngeneic HSCT studies, (211)At-B10-30F11 RIT improved t
81 trate that human induced Treg cells suppress syngeneic human ILC2s through ICOSL to control airway in
82 l alterations in tumor cells in vitro and in syngeneic immune-competent mouse models.
83 phatic drainage from murine B16 melanomas in syngeneic, immune-competent C57Bl/6 mice is associated w
84 ompared with an otherwise identical IgG in a syngeneic immunocompetent animal, and we identify TNFalp
85 y, and immunosuppressive microenvironment in syngeneic immunocompetent mice and should prove useful f
86 otopic malignant gliomas were established in syngeneic immunocompetent mice and then treated with den
87 rexpression inhibited growth of HCC cells in syngeneic immunocompetent mice.
88                                  Here, using syngeneic immunocompetent mouse tumor models, we reveal
89              By comparing DARA efficacy in a syngeneic in vivo tumor model using FcRgamma-chain knock
90 in-isolated microglia in treatment of murine syngeneic intracranial malignant gliomas.
91  T cell proliferation in vitro, rejection of syngeneic iPSC-derived EBs/tissue-specific cells (TSCs)
92      Thus, differentiated cells derived from syngeneic iPSCs do not appear to be rejected after trans
93 e of an immune response to undifferentiated, syngeneic iPSCs.
94 ockade leads to a significant improvement of syngeneic islet engraftment and of allogeneic islet graf
95  inflammatory response in islets and improve syngeneic islet graft survival in mice.
96         Diabetic mice were transplanted with syngeneic islets placed under the kidney capsule (KC) or
97                                  Six hundred syngeneic islets subcutaneously transplanted into the pr
98 etic C57BL/6 mice were transplanted with 350 syngeneic islets through the portal vein and treated onc
99 of suboptimal islet transplants of 50 or 125 syngeneic islets to achieve glycemic control in STZ-indu
100 plantation of a marginal mass (50 islets) of syngeneic islets treated with nanoparticle conjugates ta
101 xpression of TGF-beta prevented rejection of syngeneic islets, that there was reduction of dendritic
102 ols) were given subcutaneous injections of a syngeneic KPC-derived PDAC cell line.
103 iatrogenic interference), allogeneic but not syngeneic leukocytes could induce a rapid (after 1 d) ac
104                                              Syngeneic (LEW-LEW) (n = 4) and allogeneic (BN-LEW) (n =
105 acity in NFAT5-deficient macrophages against syngeneic Lewis lung carcinoma and ID8 ovarian carcinoma
106                                       In the syngeneic Lewis-to-Lewis rat model of kidney transplanta
107  used systemically to treat established BCL1 syngeneic lymphoma, and therapy is lost when using a mou
108 male mice of inbred strain CBA do not reject syngeneic male skin grafts even though they mount a T-ce
109 R4 blockade resulted in significantly better syngeneic marginal mass islet engraftment and in indefin
110 for mAb-induced therapy of both subcutaneous syngeneic melanoma and human breast cancer xenografts.
111 lidated a mouse model of endometriosis using syngeneic menstrual endometrial tissue introduced into t
112 lignancy (n = 5/group), the latter through a syngeneic metastasis approach.
113 cle for doxorubicin delivery (CP-Dox) in the syngeneic metastatic murine models 4T1 and Lewis lung ca
114  were subcutaneously injected into flanks of syngeneic mice and tumor growth was assessed.
115  vivo, it significantly enhances survival in syngeneic mice bearing intracerebral 005 tumors.
116                                           In syngeneic mice bearing two simultaneously implanted tumo
117 ailed to grow when transplanted into normal, syngeneic mice but grew progressively in immunosuppresse
118 promoted the tumor growth in immunocompetent syngeneic mice but not in immunocompromised or Treg cell
119 is could be adoptively transferred to naive, syngeneic mice by CD4(+) T cells.
120 tly, we showed that generation of tumours in syngeneic mice by cells devoid of mitochondrial (mt) DNA
121 NAs against p63 into the mammary fat pads of syngeneic mice delays tumor growth in vivo.
122                                        Using syngeneic mice infected acutely or chronically with 6 di
123  vitro, and those cells were inoculated into syngeneic mice mammary fat pads.
124 r accomplishing robust anti-PDAC immunity in syngeneic mice through the induction of immunogenic cell
125 coma cells were injected into the spleens of syngeneic mice to isolate tumour sub-populations that co
126 ts in complete FC-muMCL1 tumor regression in syngeneic mice via NK- and T-cell-dependent mechanisms.
127 cle or PAHSA and splenic CD4(+) T cells from syngeneic mice were co-cultured to assess antigen presen
128 lls distributed predominantly to the lung of syngeneic mice, a frequent site of breast cancer metasta
129 d for tumor cells to grow and metastasize in syngeneic mice, a surprising finding given that other in
130  line recapitulated mast cell recruitment in syngeneic mice, demonstrating that this cell state can d
131 e tumorigenesis and lung metastasis model in syngeneic mice, depletion of LKB1 markedly increased tum
132                                     In obese syngeneic mice, metformin treatment mimicked the effects
133 cells were transplanted into 3-day wounds of syngeneic mice, only CD206(+)/CD301b(+) macrophages sign
134                                           In syngeneic mice, shikonin and cisplatin together, but not
135 the growth of transplantable B16 melanoma in syngeneic mice, which is accompanied by enhanced antitum
136 uced lymphatic dissemination of EMT cells in syngeneic mice.
137 are directly implanted into the left lobe of syngeneic mice.
138 in a triple-negative 4T1 breast carcinoma in syngeneic mice.
139 ble in a cohort of contemporaneously housed, syngeneic mice.
140 tic leukemia when infused into unconditioned syngeneic mice.
141 tch in species but, surprisingly, also for a syngeneic mismatch in sex.
142 tion-induced (10 Gy) tumor growth delay in a syngeneic model (C3H) but not immunosuppressed (Nu/Nu) s
143                       In vivo, 4i in a mouse syngeneic model demonstrated high antitumor activity whi
144 eatment in immune competent mice utilizing a syngeneic model of mammary tumor growth in FVB mice.
145                                         In a syngeneic model of melanoma brain metastasis, a combinat
146 total activity for (177)Lu-PSMA-617 RLT in a syngeneic model of murine prostate cancer.
147 tivity resulted in the highest efficacy in a syngeneic model of murine prostate cancer.
148 We previously showed that ID8, a widely-used syngeneic model of ovarian cancer, lacked any of the fre
149 r development was investigated using the ID8 syngeneic model of ovarian cancer.
150  culminating in improvement in survival in a syngeneic model of ovarian peritoneal carcinomatosis.
151                                         In a syngeneic model of tumor progression, subcutaneous injec
152 tastatic gene signature' derived from murine syngeneic model predicts poor patient survival in the ma
153 inst established B cell lymphoma in a BALB/c syngeneic model system.
154 apparent body weight loss in the murine CT26 syngeneic model, after oral administration of 400 mg/kg.
155 C57BL/6J (allogeneic model, n = 17) and C3H (syngeneic model, n = 13) mice.
156                                         In a syngeneic model, similarly engineered melanoma-reactive
157 I-402257 reduced MM growth in an orthotopic, syngeneic model, when used as a single agent, and more s
158 ls rendered protection against melanoma in a syngeneic model, with decreased expression of PD-L1 and
159 effects of CD47 blockade were greater in the syngeneic model.
160 ompared these activities using two different syngeneic models for normal and oncogene-transformed hum
161 d (AP20187) triggered apoptosis in 2 in vivo syngeneic models of bone tumor growth in which apoptosis
162 g in mice enhances antitumor immunity in two syngeneic models of cancer.
163  and type II natural killer T (NKT) cells in syngeneic models of colorectal and renal cancer.
164 h and prolong survival in both xenograft and syngeneic models of glioblastoma.
165 n mouse triple-negative breast cancer (TNBC) syngeneic models with a TGI (tumor growth inhibition) of
166 antitumor efficacy of immunomodulator Abs in syngeneic models.
167 e compared more than 3700 compounds in three syngeneic mouse embryonic stem cell (mESC) lines: htt(-/
168 d in synergistic activity in two independent syngeneic mouse glioma models by promoting migration of
169 ortalized normal human astrocytes (NHAs) and syngeneic mouse glioma models, the introduction of mutan
170  tempered by evidence that undifferentiated, syngeneic mouse iPSCs are immunogenic upon transplantati
171                                              Syngeneic mouse islets (150) were transplanted either un
172                                              Syngeneic mouse islets were transplanted subcutaneously
173 iability probe to immune cells isolated from syngeneic mouse MB49 bladder tumors, spleens, and tumor-
174 icle-encapsulated paclitaxel in subcutaneous syngeneic mouse melanoma and orthotopic xenograft lung c
175 istently, inflammatory MITF(low)/c-Jun(high) syngeneic mouse melanomas recruit myeloid immune cells i
176  high metastatic potential and an orthotopic syngeneic mouse model and in vitro using a CXCR2 small-m
177 mor activity of K145 was also confirmed in a syngeneic mouse model by implanting murine breast cancer
178                                      Using a syngeneic mouse model for GB, we tested whether local de
179  vivo, tumors were induced in an orthotopic, syngeneic mouse model of advanced stage EOC.
180                     In this study, we used a syngeneic mouse model of BRAF(V600E)-driven melanoma to
181                                         In a syngeneic mouse model of endometriosis, IL-33 injections
182                                         In a syngeneic mouse model of glioblastoma, administering TGF
183 -FAK mechanosignaling and Akt signaling in a syngeneic mouse model of metastasis.
184 2 displayed potent efficacy in an aggressive syngeneic mouse model of multiple myeloma and prolonged
185 riggered complete regressions in the Ehrlich syngeneic mouse model of solid tumor.
186                                An orthotopic syngeneic mouse model resulted in tumours with 2.3-fold
187 e experimental lung metastasis model and the syngeneic mouse model.
188 osis using patient samples, cell lines and a syngeneic mouse model.
189 copal effects on both 4T1 and TUBO bilateral syngeneic mouse models further demonstrate that ZnP@pyro
190                                        Using syngeneic mouse models of breast cancer, melanoma, and c
191  upregulation on tumor cells in a variety of syngeneic mouse models of cancer.
192 eriments and mouse transcriptome analyses in syngeneic mouse models, we provide evidence that tumour-
193 ced neovascularization using two independent syngeneic mouse models.
194 the lung and liver in multiple xenograft and syngeneic mouse models.
195 y report complete regression of tumors using syngeneic mouse models.
196 and therapeutic efficacy of PD-1 blockade in syngeneic mouse models.
197 es displayed equal oncolytic efficacies in a syngeneic mouse myeloma model.
198 grees C in UW solution, were transplanted to syngeneic mouse recipients.
199 n of 10(6) 5T33 mouse myeloma cells into the Syngeneic mouse strain C57BL/KaLwRij resulted in a rapid
200 nation with a clinical chemotherapeutic to a syngeneic mouse transplantation model of hepatic colorec
201 aded LPS-Lips in HepG2 cells in vitro and in syngeneic mouse transplants in vivo.
202 , and oral RA190 treatment retarded HPV16(+) syngeneic mouse tumor growth, without affecting spontane
203                          Using an orthotopic syngeneic mouse tumor model, we make the striking observ
204                                           In syngeneic mouse tumor models, 1F5 showed potent antitumo
205  survival improvements are achieved in three syngeneic mouse tumor models, including complete respons
206  in the tumor microenvironment using several syngeneic mouse tumor models.
207  lines, we performed a secondary screen in a syngeneic murine AML model driven by the MLL-AF9 oncogen
208 Dox-LTSLs were injected intravenously into a syngeneic murine breast cancer model (6 mg Dox/kg body w
209 tivity of tumor-associated immune cells in a syngeneic murine breast cancer model.
210                              The heterotopic syngeneic murine head and neck cancer model (mEER) cause
211 a in vitro and in vivo in KIR transgenic and syngeneic murine lymphoma models.
212 ccine-induced antitumor immune response in a syngeneic murine model of B16 melanoma.
213  in the process of glioma progression in the syngeneic murine model of glioma.
214                                      Using a syngeneic murine model, we investigated the changes that
215 ays, alternative methods of quantitation and syngeneic murine models have all led to an appreciation
216 in a physiologic setting, using preclinical, syngeneic murine models of hematologic malignancies and
217                 Both in vitro and in vivo in syngeneic murine models of islet transplantation, the fu
218 esmoplastic human lung cancer xenografts and syngeneic murine pancreatic cancers in an immune-indepen
219                                           In syngeneic murine rhabdomyosarcoma models, we found that
220 opically implanted human tumor xenograft and syngeneic murine tumor models.
221    Tumor targeting of DAB4 was selective for syngeneic murine tumors and for human tumor xenografts o
222 dritic cell vaccines in two different murine syngeneic murine tumors.
223 ntraportally with 2500 ferucarbotran-labeled syngeneic (n=10) or allogeneic (n=12) islet equivalents
224 ls are similarly capable to polarize ex vivo syngeneic naive CD4(+) T cells toward a T-bet(+)IFN-gamm
225 oietic stem/progenitor cells into irradiated syngeneic or allogeneic young or aged recipients resulte
226 cts were elicited by 3'3'-cGAMP injection in syngeneic or immunodeficient mice grafted with multiple
227 oma (CTCL) lines, HH and Hut78, were used in syngeneic or standard NSG mouse models to demonstrate a
228 ses PDAC tumour cell growth in xenograft and syngeneic orthotopic animal models, and induces growth i
229                           Here we describe a syngeneic orthotopic HCC model in immunocompetent mice w
230                                In an in vivo syngeneic orthotopic model, inhibition of TGF-beta signa
231 cells in the tumor microenvironment, using a syngeneic orthotopic mouse model of epithelial ovarian c
232                               We also used a syngeneic orthotopic PDAC mouse model to study tumor gro
233 ncreased survival in both obesity-driven and syngeneic orthotopic PDAC mouse models.
234                              Here, we used a syngeneic, orthotopic mouse model of breast cancer to st
235                          Using two different syngeneic, orthotopic tumor implant models of breast can
236  therapeutic response in an in vivo primary, syngeneic p53(null) claudin-low tumor model that is norm
237 H mutations in immune response, we created a syngeneic pair mouse model for mutant IDH1 (muIDH1) and
238 e Her2/Neu-driven breast cancer model and in syngeneic pancreatic tumor (Pan02) xenografts.
239                          Here, we analyzed 2 syngeneic primary human osteosarcoma cell lines that exh
240 ction of Mobilan into subcutaneously growing syngeneic prostate tumors in immunocompetent hosts impro
241 antagonist, etanercept (ETN), for studies in syngeneic rat hepatocyte transplantation systems.
242 ntly, low-purity (30:70% endocrine:exocrine) syngeneic rat islet preparations displayed function equi
243 rgeting the Lewis Y antigen over 7 d using a syngeneic rat model of colon carcinoma.
244   In vivo experiments were conducted using a syngeneic rat orthotopic CCA model.
245                                    We used a syngeneic rat renal transplantation model of IRI with bi
246 widely on human ovarian tumors, along with a syngeneic rat tumor model expressing human FRalpha.
247 livers, characterized, and transplanted into syngeneic recipients.
248 tion and subsequent associated graft loss in syngeneic recipients.
249 mune disease that leads to severe wasting in syngeneic recipients.
250 n vitro and after their transplantation into syngeneic recipients.
251 e UW solution for 20 h, were transplanted to syngeneic recipients.
252 ed of autophagosomes (DRibbles) derived from syngeneic sarcomas could induce cross-reactive T-cell re
253 eneic skin transplantation alone (n = 6), or syngeneic skin transplantation (n = 4).
254                                              Syngeneic spontaneous and experimental metastasis models
255 abeled TPP is continuously internalized into syngeneic, spontaneous, chemically/genetically induced a
256  microenvironment role of RAGE, we performed syngeneic studies with orthotopically injected breast ca
257                          Here, we utilized a syngeneic subcutaneous murine model of B16F10 melanoma t
258 alloreactive T cells and was not observed in syngeneic T cells during homeostatic proliferation.
259 ultaneous transfer of genetically engineered syngeneic T cells expressing a chimeric antigen receptor
260 the role of BLT1 in antitumor immunity using syngeneic TC-1 cervical cancer model, and observed accel
261 fragmentation one week before engraftment of syngeneic TC1 or LL3 tumor cells and tumor analysis four
262 essive myeloid-derived suppressor cells in a syngeneic TNBC mouse model.
263                                      Using a syngeneic TP53-null mouse model of breast cancer, we ide
264                                              Syngeneic transplant experiments utilizing green fluores
265 duced more VEC proliferation than those from syngeneic transplant recipients (P = 0.03).
266 fting to LSC-deficient mice in xenogeneic or syngeneic transplantation models.
267 at P2X1R is augmented in both allogeneic and syngeneic transplantation.
268 enic changes appeared due to conditioning or syngeneic transplantation.
269 ate tumorigenic from nontumorigenic cells in syngeneic transplants.
270 rradiated and transplanted 3 days later with syngeneic Trp53-null mammary fragments.
271 y (5 weeks) or at maturation (10 weeks) with syngeneic Trp53-null mammary tissue fragments and monito
272 two in vivo experimental systems: an ectopic syngeneic tumor (Lewis lung carcinoma) and an orthotopic
273 ytokine response and potent cytotoxicity for syngeneic tumor cells upon activation, as do human CD8al
274 -CpG-B could substantially protect mice from syngeneic tumor challenge, even after 4 mo of vaccinatio
275                                     Further, syngeneic tumor experiments revealed that the absence of
276 pression within T cells is required to limit syngeneic tumor growth and promote IFNgamma production b
277 r-infiltrating CD8 expression in preclinical syngeneic tumor immunotherapy models including antigen-s
278                     PHD3 overexpression in a syngeneic tumor model resulted in fewer liver metastases
279 ement membrane, whereas its attenuation in a syngeneic tumor model resulted in reduced metastatic col
280  demonstrate that, in three different murine syngeneic tumor models (B16, SCC7, and 4T1), loss of the
281 ne cells to eliminate large tumor burdens in syngeneic tumor models and a genetically engineered mous
282 sed metastatic dissemination in xenograft or syngeneic tumor models in vivo.
283 and inflammatory analysis of four additional syngeneic tumor models revealed that tumors can induce f
284 any of the effects of anti-mouse GITR mAb in syngeneic tumor models, decreasing both Treg numbers and
285  imaging inflammation in both xenogeneic and syngeneic tumor models, which resulted in detection of t
286 plete protection from tumor engraftment in a syngeneic tumor vaccine model, inhibited neutrophil extr
287 mes was similar to non-targeted liposomes in syngeneic tumor-bearing FVB mice and C-LPP liposomes red
288    The peptides were injected into rats with syngeneic tumors and mice with orthotopic or xenograft t
289 y was CD8 dependent and controlled growth of syngeneic tumors even when an adoptive immunotherapy was
290 C57BL6/KaLwRij mice bearing murine 5TGM1-GFP syngeneic tumors generated after intravenous injection v
291 ring peritoneal MKN-45P xenografts and CT-26 syngeneic tumors with IP linTT1-D(KLAKLAK)2-NWs resulted
292 tivity in orthotopic human tumor xenografts, syngeneic tumors, and a genetic model of pancreatic canc
293 within T cells during the immune response to syngeneic tumors.
294 munotargeting of xCT in mice challenged with syngeneic tumorsphere-derived cells delayed established
295 es and this correlated with no difference in syngeneic tumour growth between wild-type, Claudin 14-he
296 ma model SMA560 injected intracranially into syngeneic VM/Dk mice, analyzing animals at various posti
297 plantation (major histocompatibility complex syngeneic) was modeled by transplanting hearts from A-Tg
298   The stroke phenotype can be transferred to syngeneic wild-type mice via Tgfbr2(Myeko) bone marrow t
299 is in experimental as well as in spontaneous syngeneic wild-type mouse models.
300 lls are directly implanted into the lungs of syngeneic WT mice or mice globally deficient in 5-LO (5-

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。
 
Page Top